KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Investments: 2014-2023

Historic Long-Term Investments for Pacira BioSciences (PCRX) over the last 5 years, with Dec 2023 value amounting to $2.4 million.

  • Pacira BioSciences' Long-Term Investments fell 93.52% to $2.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.4 million, marking a year-over-year decrease of 93.52%. This contributed to the annual value of $2.4 million for FY2023, which is 93.52% down from last year.
  • According to the latest figures from Q4 2023, Pacira BioSciences' Long-Term Investments is $2.4 million, which was down 70.90% from $8.3 million recorded in Q1 2023.
  • Pacira BioSciences' Long-Term Investments' 5-year high stood at $95.5 million during Q4 2020, with a 5-year trough of $2.4 million in Q4 2023.
  • Over the past 3 years, Pacira BioSciences' median Long-Term Investments value was $17.4 million (recorded in 2022), while the average stood at $20.1 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 1,484.13% in 2019, then plummeted by 93.52% in 2023.
  • Over the past 5 years, Pacira BioSciences' Long-Term Investments (Quarterly) stood at $64.8 million in 2019, then skyrocketed by 47.32% to $95.5 million in 2020, then declined by 0.42% to $35.0 million in 2021, then reached $37.2 million in 2022, then slumped by 93.52% to $2.4 million in 2023.
  • Its last three reported values are $2.4 million in Q4 2023, $8.3 million for Q1 2023, and $37.2 million during Q4 2022.